The 5 Most Common Viable Sampling Errors - On Demand
-
Register
- Prices available after logging in
With the increase in viable sampling frequency, more sterile compounding facilities are taking sample collection, incubation, and analysis in-house. This is a major undertaking that requires knowledgeable, dedicated staff to ensure not only compliance with USP General Chapter <797>, but also the incorporation of microbiological best practices that are not addressed in the chapter. This presentation will address 5 common errors that sterile compounding facilities make when taking on viable sampling and incubation.
Learning Objectives:
- Identify potential shortcomings in your sterile compounding facility's viable sampling program.
- Discuss changes that can be made to the viable sampling program to ensure compliance.
- List industry standards and guides that aid in the development of a robust viable sampling program.
Abby Roth, BS, CMQ/OE
Founder
Pure Microbiology
Abby Roth, founder of Pure Microbiology, has over 18 years of experience in supporting the testing and consulting needs of the pharmaceutical, medical device, and compounding industries. Her background in pharmaceutical microbiology includes extensive knowledge of environmental monitoring. Abby served as a USP Compounding EC member during the 2015-2020 cycle. She is an involved member of the Controlled Environment Testing Association (CETA), serving on the Board of Directors, speaking at its annual meetings, and chairing committees for the revision of four CETA Application Guides. Abby has been invited to speak for state boards of pharmacy and for national organizations.
No Disclosures to Report
Key:
Complete
Next
Failed
Available
Locked